Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Inmedix

Explore full profile

Home | Inmedix, Innovative Medical Discovery

Normandy Park, United StatesFounded 2006Health
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Inmedix and the history behind them.

About Inmedix

Inmedix brings an essential new diagnostic, a new cloud platform and a new strategy to transform medicine, beginning with autoimmune disease .

Next-generation Inmedix heart rate variability (HRV), the Inmedix Cloud diagnostics platform and its concept of Immuno-autonomics are the essence of applied transitional medicine to understand why patients respond differently to the same treatment.

For autoimmune diseases like rheumatoid arthritis (RA), lupus (SLE) and multiple sclerosis (MS), the conundrum points to stress - traditionally thought of as a 'soft' science. But now through innovative, international research and undaunted clinical validation, this soft science is becoming increasingly hardened into its distinctive and actionable biology

The autonomic nervous system, or ANS, within the brain modulates stress to enhance survival. Adrenaline (epinephrine) helps one escape the tiger to survive, but it also drives immune aggression. For an autoimmune disease, stress result in disastrous consequences for patients. In fact, 97% of UK patients with RA claimed in 2019 that stress caused disease flares.

There is always a cause (or causes) for either treatment benefit and failure. Stress and immuno-autonomics appear to be an important target to understand why patients with autoimmune diseases respond differently to the same treatment.

And, what you do not measure, you cannot manage. ANS stress state may be the most overlooked element of precision, personalized medicine. The trick is to measure ANS state accurately - something routinely and sadly taken for granted. Inmedix offers the precision medicine has been waiting for. See our new video at www.inmedix.com explaining immuno-autonomics.

Source: Dealroom company data

At a glance

Founded
2006
Headquarters
Normandy Park, United States
Sector
Health

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Keiretsu Forum Northwest
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States71.4%
🇬🇧 United Kingdom28.6%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Inmedix on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inmedix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.